Biomarkers for Alzheimer's disease

Showing the way or leading us astray?

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a 'presymptomatic' stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine 'go- no go' decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.

Original languageEnglish (US)
Title of host publicationAdvances in Alzheimer's Disease
Pages371-376
Number of pages6
Volume3
DOIs
StatePublished - 2012

Publication series

NameAdvances in Alzheimer's Disease
Volume3
ISSN (Print)22105727
ISSN (Electronic)22105735

Fingerprint

Alzheimer Disease
Biomarkers
Asymptomatic Diseases
Patient Selection
Clinical Trials
Pharmaceutical Preparations
Therapeutics

Keywords

  • Alzheimer's disease
  • biomarkers
  • clinical trials

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Quinn, J. (2012). Biomarkers for Alzheimer's disease: Showing the way or leading us astray? In Advances in Alzheimer's Disease (Vol. 3, pp. 371-376). (Advances in Alzheimer's Disease; Vol. 3). https://doi.org/10.3233/978-1-61499-154-0-371

Biomarkers for Alzheimer's disease : Showing the way or leading us astray? / Quinn, Joseph.

Advances in Alzheimer's Disease. Vol. 3 2012. p. 371-376 (Advances in Alzheimer's Disease; Vol. 3).

Research output: Chapter in Book/Report/Conference proceedingChapter

Quinn, J 2012, Biomarkers for Alzheimer's disease: Showing the way or leading us astray? in Advances in Alzheimer's Disease. vol. 3, Advances in Alzheimer's Disease, vol. 3, pp. 371-376. https://doi.org/10.3233/978-1-61499-154-0-371
Quinn J. Biomarkers for Alzheimer's disease: Showing the way or leading us astray? In Advances in Alzheimer's Disease. Vol. 3. 2012. p. 371-376. (Advances in Alzheimer's Disease). https://doi.org/10.3233/978-1-61499-154-0-371
Quinn, Joseph. / Biomarkers for Alzheimer's disease : Showing the way or leading us astray?. Advances in Alzheimer's Disease. Vol. 3 2012. pp. 371-376 (Advances in Alzheimer's Disease).
@inbook{47b5df9d804542e584ff158838a4031b,
title = "Biomarkers for Alzheimer's disease: Showing the way or leading us astray?",
abstract = "The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a 'presymptomatic' stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine 'go- no go' decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.",
keywords = "Alzheimer's disease, biomarkers, clinical trials",
author = "Joseph Quinn",
year = "2012",
doi = "10.3233/978-1-61499-154-0-371",
language = "English (US)",
isbn = "9781614991533",
volume = "3",
series = "Advances in Alzheimer's Disease",
pages = "371--376",
booktitle = "Advances in Alzheimer's Disease",

}

TY - CHAP

T1 - Biomarkers for Alzheimer's disease

T2 - Showing the way or leading us astray?

AU - Quinn, Joseph

PY - 2012

Y1 - 2012

N2 - The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a 'presymptomatic' stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine 'go- no go' decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.

AB - The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a 'presymptomatic' stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine 'go- no go' decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.

KW - Alzheimer's disease

KW - biomarkers

KW - clinical trials

UR - http://www.scopus.com/inward/record.url?scp=84877999268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877999268&partnerID=8YFLogxK

U2 - 10.3233/978-1-61499-154-0-371

DO - 10.3233/978-1-61499-154-0-371

M3 - Chapter

SN - 9781614991533

VL - 3

T3 - Advances in Alzheimer's Disease

SP - 371

EP - 376

BT - Advances in Alzheimer's Disease

ER -